Carlyle, a private equity firm, and Atmas Health, a healthcare investment platform, agreed to acquire the Vantive kidney care segment of Baxter, a global medtech company, for $3.8bn. "Today's announcement represents another critical step forward in the strategic transformation process we announced in early 2023. As a result of this proposed transaction, Baxter will emerge a more focused and more efficient company, better positioned to redefine healthcare delivery and advance innovation that benefits patients, customers and shareholders. I am confident that, under Carlyle's stewardship and Chris Toth’s leadership, the Vantive team will continue to build on the business's 70-year legacy as a pioneer in kidney disease and vital organ therapies," José (Joe) E. Almeida, Baxter Chair, President and CEO.